Press release from the extraordinary general meeting of Vicore Pharma

At the extraordinary general meeting (the “EGM”) of Vicore Pharma Holding AB (publ) (the “Company”) held on 7 January 2019, the following resolutions were passed.

Resolution to change the articles of association

The EGM resolved to change the articles of association in accordance with the board of directors’ proposal. Through the resolution, the articles of association’s limits for share capital and number of shares were changed, and places where the Company shall be able to hold its general meetings were added. Going forward, the Company may hold its general meetings in Gothenburg and Stockholm, in addition to Mölndal.

Approval of the board of directors’ resolution to issue shares

The EGM resolved to approve the board of directors’ resolution to issue 9,414,706 shares at a subscription price of SEK 17 per share from 30 November 2018. The right to subscribe for the new shares shall, with deviation from the shareholders’ pre-emption rights, be granted a number of selected Swedish and international long-term institutional investors and sector specialist funds who were identified through the book building procedure carried out prior to the board of directors’ resolution. The objective of the resolution and the reasons for the deviation from the shareholders’ pre-emption rights are to strengthen the institutional ownership structure in the Company as well as, in a timely and cost-efficient manner, enable the financing of the continued development of the Company’s drug development programs VP01 and VP02.

For further information regarding the resolutions to change the articles of association and approval of the board of directors’ resolution to issue shares, please refer to the Company’s webpage www.vicorepharma.com.

Mölndal, 7 January 2019 

Vicore Pharma Holding AB (publ)

For further information, please contact:
Carl-Johan Dalsgaard, CEO
Phone: +46 70 975 98 63
E-mail: carl-johan.dalsgaard@vicorepharma.com 

Hans Jeppsson, CFO
Phone: +46 70 553 14 65  
E-mail: hans.jeppsson@vicorepharma.com

The information was submitted for publication through the agency of the contact persons set out above on 7 January 2019 at 15.30 CET.

About Vicore Pharma Holding AB (publ)
Vicore Pharma AB is focused on the development of drugs for the treatment of interstitial lung diseases. The company’s two major development programs, VP01 (C21) and VP02 (IMiD), act through the AT2 receptor and is an immunomodulatory drug substance class being developed for local treatment, respectively. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. VP02 has in earlier experiments shown an effect in e.g. idiopathic pulmonary fibrosis with another administration form which, however, has limited its continued development. VP02 is being developed for local treatment in order to e.g. overcome such shortcomings. The company is based in AstraZeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com 

Tags:

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links